← board
CTOR
distress 4/10 · elevated risk$0.56-2%today-80% from 52w high
Lead: recurrent/refractory gynecologic cancers (ovarian · est. market ~$8B (approx, global)
Revenue
pre-revenue
Liquidity
$52M
Runway
6.4 yrs
Shares 1y
+19%
Price & events
-49.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.0%
1D
-17.7%
1W
-18.0%
1M
-42.6%
3M
-50.3%
6M
-69.1%
1Y
-95.1%
2Y
—
5Y
-94.4%
All
Overview
- Market Cap
- $52.21M
- Volume
- 22.28K
- 52 Week Range
- $0.49 – $2.82
- Total Shares
- 92.98M
- Float Shares
- 17.72M
- Short %
- 2.70%
- % Held by Insiders
- 77.51%
- % Held by Institutions
- 15.32%
- RVOL
- 0.40x
- Beta
- 3.48
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 3
- later this yearGuided 40%conferencedata presentationsecondaryPhase 1LYMPHIR · Full safety and clinical efficacy results to be presented at an international cancer conferenceSEC 8-K
- 2026-04-29partnershipLYMPHIR · Initial shipment to Europe via distribution partner for Named Patient Programs.SEC 8-K
- November 8-10, 2024conferencedata presentationsecondaryPhase 1LYMPHIR · Poster presentation at SITC 2024 Annual Meeting showing preliminary efficacy and safety data for pembrolizumab+LYMPHIR combo.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2025-09-23Maxim GroupHold → Buy
- 2025-05-23Maxim GroupBuy → Hold
- 2024-11-27Maxim GroupBuy
- 2024-08-13EF HuttonBuy
Competitors — recurrent/refractory gynecologic cancers (ovarian
- none identified
Recent news
- 2026-07-21Citius Oncology expands sales team for LYMPHIR launch - Investing.com
- 2026-07-21Citius Oncology Reports Near-100% Payer Coverage for LYMPHIR - Stock Titan
- 2026-07-21Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption - PR Newswire
- 2026-07-15Citius Oncology (Nasdaq: CTOR) sets $18M stock deal at $1.09 to back LYMPHIR launch - Stock Titan
- 2026-07-15Citius Oncology (CTOR) Registration filing Summary - Quartr
- 2026-07-15Citius Oncology (CTOR) Registration filing Summary - Quartr
- 2026-07-11CTXR News | CITIUS PHARMACEUTICALS INC (NASDAQ:CTXR) - ChartMill
- 2026-06-26Price to sales forward of Citius Oncology, Inc. – NASDAQ:CTOR - TradingView
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.